Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback